High safety and immunogenicity were observed in an open-label, single-armed phase I clinical trial (NCT01250470), in which nine recurrent-malignant-glioma patients were vaccinated with a 15-amino acid-long survivin (also known as baculoviral inhibitor of apoptosis repeat-containing 5, BIRC5) peptide, containing different eight-to-ten-amino acid immunoreactive epitopes with the same C57M mutation [62]. The gene discussed is BIRC5; the disease is malignant glioma.